Efficacy and safety evaluation based on time from completion of radiotherapy to randomization with durvalumab or placebo in pts from PACIFIC

Corinne Faivre Finn, David Robert Spigel, Suresh Senan et al. · Annals of Oncology · 2018

Background: In the Ph 3 PACIFIC study of durvalumab (durva) versus placebo (pbo) in pts with stage III, locally advanced (LA), unresectable NSCLC after concurrent chemoradiotherapy (cCRT), PFS was significantly longer with durva (stratified HR 0.52; 95% CI 0.42–0.65; P<0.0001). This exploratory analysis characterizes outcomes based on time from completing RT to Tx.

Cited by 34 works. doi:10.1093/annonc/mdy291

Authors